Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer, has revolutionized cancer care by targeting the HER2 receptor, which is overexpressed in a subset of breast cancer cases. As the demand for more affordable treatments grows, trastuzumab biosimilars have emerged as a viable solution, offering improved access to essenti